Individualized Dosimetry of Kidney and Bone Marrow in Patients Undergoing 177Lu-DOTA-Octreotate Treatment
Open accessThe DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Abstract
UNLABELLED: The organs at risk in radionuclide therapy with (177)Lu-octreotate are the bone marrow and the kidneys. The primary aim of this study was to develop an individualized dosimetry protocol for the bone marrow. The secondary aim was to identify those patients, undergoing fractionated therapy with 7.4 GBq/cycle, who first reached an accumulated dose of either 2 Gy to the bone marrow or 23 Gy to the kidneys. METHODS: Two hundred patients with metastatic neuroendocrine tumors with high somatostatin receptor expression were included. After the administration of 7.4 GBq of (177)Lu-octreotate, blood samples were drawn 6 times within the first 24 h. In 50 patients, additional blood samples were obtained at 96 and 168 h. Moreover, urine was collected from 30 patients during the first 24 h. Planar whole-body and SPECT/CT images over the abdomen were acquired at 24, 96, and 168 h after the infusion. Calculation of the absorbed radiation dose to the bone marrow was based on blood and urinary activity curves combined with organ-based analysis of the whole-body images. The absorbed dose to the kidney was calculated from the pharmacokinetic data obtained from SPECT/CT. RESULTS: For a single cycle of 7.4 GBq, the absorbed dose to the bone marrow and the kidney ranged from 0.05 to 0.4 Gy and from 2 to 10 Gy, respectively. In 197 of 200 patients, the kidneys accumulated an absorbed dose of 23 Gy before the bone marrow reached 2 Gy. Between 2 and 10 cycles of (177)Lu-octreotate could be administered before the upper dose limit for the individual patient was reached. CONCLUSION: A method based on repeated whole-body imaging in combination with blood and urinary activity data over time was developed to determine the absorbed dose to the bone marrow. The dose-limiting organ was the kidney in 197 of 200 patients. In 50% of the patients, more than 4 cycles of 7.4 GBq of (177)Lu-octreotate could be administered, whereas 20% of the subjects were treated with fewer than 4 cycles. Individualized absorbed dose calculation is essential to optimize the therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tolerance of normal tissue to therapeutic irradiation
Emami, B., Lyman, J., Brown, A., Cola, L., Goitein, M., Munzenrider, J. E., Shank, B., Solin, L. J., & Wesson, M. (1991) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/0360-3016(91)90171-y · Cited by 4,488
Kwekkeboom, D. J., de Herder, W. W., Kam, B. L., van Eijck, C. H., van Essen, M., Kooij, P. P., Feelders, R. A., van Aken, M. O., & Krenning, E. P. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.2553 · Cited by 1,456
Kwekkeboom, D. J., Teunissen, J. J., Bakker, W. H., Kooij, P. P., de Herder, W. W., Feelders, R. A., van Eijck, C. H., Esser, J.-P., Kam, B. L., & Krenning, E. P. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.08.066 · Cited by 657
Imhof, A., Brunner, P., Marincek, N., Briel, M., Schindler, C., Rasch, H., Mäcke, H. R., Rochlitz, C., Müller-Brand, J., & Walter, M. A. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.7873 · Cited by 641
Bodei, L., Cremonesi, M., Ferrari, M., Pacifici, M., Grana, C. M., Bartolomei, M., Baio, S. M., Sansovini, M., & Paganelli, G. (2008) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-008-0778-1 · Cited by 428
Peptide receptor radionuclide therapy with 177Lu-DOTATATE: the IEO phase I-II study
Bodei, L., Cremonesi, M., Grana, C. M., Fazio, N., Iodice, S., Baio, S. M., Bartolomei, M., Lombardo, D., Ferrari, M. E., Sansovini, M., et al. (2011) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-011-1902-1 · Cited by 424
Valkema, R., Pauwels, S. A., Kvols, L. K., Kwekkeboom, D. J., Jamar, F., de Jong, M., Barone, R., Walrand, S., Kooij, P. P. M., Bakker, W. H., et al. (2005) · PubMed · Cited by 389
Barone, R., Borson‐Chazot, F., Valkema, R., Walrand, S., Chauvin, F., Gogou, L., Kvols, L. K., Krenning, E. P., Jamar, F., & Pauwels, S. A. (2005) · PubMed · Cited by 356
Somatostatin receptor-targeted radionuclide therapy of tumors: Preclinical and clinical findings
de Jong, M., Valkema, R., Jamar, F., Kvols, L. K., Kwekkeboom, D. J., Breeman, W. A. P., Bakker, W. H., Smith, C., Pauwels, S., & Krenning, E. P. (2002) · Seminars in Nuclear Medicine · doi:10.1053/snuc.2002.31027 · Cited by 346
MIRD Pamphlet No. 24: Guidelines for Quantitative 131I SPECT in Dosimetry Applications
Dewaraja, Y. K., Ljungberg, M., Green, A. J., Zanzonico, P. B., Frey, E. C., SNMMI MIRD Committee, Bolch, W. E., Brill, A. B., Dunphy, M., Fisher, D. R., et al. (2013) · Journal of Nuclear Medicine · doi:10.2967/jnumed.113.122390 · Cited by 336
Cited by
Ljungberg, M., Celler, A., Konijnenberg, M. W., Eckerman, K. F., Dewaraja, Y. K., & Sjögreen-Gleisner, K. (2016) · Journal of Nuclear Medicine · doi:10.2967/jnumed.115.159012 · Cited by 369
Delker, A., Fendler, W. P., Kratochwil, C., Brunegraf, A., Gosewisch, A., Gildehaus, F. J., Tritschler, S., Stief, C. G., Kopka, K., Haberkorn, U., et al. (2016) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-015-3174-7 · Cited by 322
Garske-Román, U., Sandström, M., Fröss Baron, K., Lundin, L., Hellman, P., Welin, S., Johansson, S., Khan, T., Lundqvist, H., Eriksson, B., et al. (2018) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-018-3945-z · Cited by 254
“4 GBq of (177)Lu-DOTA-octreotate before reaching either 23 Gy to the kidneys or 2 Gy to the bone marrow [17].”
BackgroundSelf-citationDose Mapping After Endoradiotherapy with 177Lu-DOTATATE/DOTATOC by a Single Measurement After 4 Days
Hänscheid, H., Lapa, C., Buck, A. K., Lassmann, M., & Werner, R. A. (2018) · Journal of Nuclear Medicine · doi:10.2967/jnumed.117.193706 · Cited by 219
Okamoto, S., Thieme, A., Allmann, J., D’Alessandria, C., Maurer, T., Retz, M., Tauber, R., Heck, M. M., Wester, H.-J., Tamaki, N., et al. (2017) · Journal of Nuclear Medicine · doi:10.2967/jnumed.116.178483 · Cited by 213
Kabasakal, L., AbuQbeitah, M., Aygün, A., Yeyin, N., Ocak, M., Demirci, E., & Toklu, T. (2015) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-015-3125-3 · Cited by 208
Del Prete, M., Buteau, F.-A., Arsenault, F., Saighi, N., Bouchard, L.-O., Beaulieu, A., & Beauregard, J.-M. (2019) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-018-4209-7 · Cited by 184
Velikyan, I., Sundin, A., Sörensen, J., Lubberink, M., Sandström, M., Garske-Román, U., Lundqvist, H., Granberg, D., & Eriksson, B. (2014) · Journal of Nuclear Medicine · doi:10.2967/jnumed.113.126177 · Cited by 176
“Individualized therapy planning with adjustment of injected radioactivity dose during peptide receptor radionuclide therapy (PRRT) of NETs is necessary because of high interpatient variability in healthy organ uptake (18).”
BackgroundSelf-citationCremonesi, M., Ferrari, M. E., Bodei, L., Chiesa, C., Sarnelli, A., Garibaldi, C., Pacilio, M., Strigari, L., Summers, P. E., Orecchia, R., et al. (2018) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-018-4044-x · Cited by 141
“10 Del Prete 2017 [33] Bergsma 2016 [35] Sandstrom 2013 [9] Kairemo 2013 [28] Bodei 2011 [27] Garkavij 2010 [24] Forrer 2009 [34] Wehrmann 2007 [21] Cremonesi 2006 [20] Kwekkeboom 2001 [19]”
MethodInfluentialReidy-Lagunes, D., Pandit-Taskar, N., O'Donoghue, J. A., Krebs, S., Staton, K. D., Lyashchenko, S. K., Lewis, J. S., Raj, N., Gönen, M., Lohrmann, C., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1026 · Cited by 112
Metadata
- Authors
- Sandström, M., Garske-Román, U., Granberg, D., Johansson, S., Widström, C., Eriksson, B., Sundin, A., Lundqvist, H., & Lubberink, M.
- Venue
- Journal of Nuclear Medicine
- Publisher
- Society of Nuclear Medicine
- Published
- 2012-12-07
- Volume
- 54
- Issue
- 1
- Pages
- 33-41
- ISSN
- 0161-5505 (ISSN-L)
- 2159-662X
- OpenAlex
- W1983680048
- Cited by
- 287
- References
- 33
- FWCI
- 5.34
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.